Tirzepatide , sold as Mounjaro for diabetes and Zepbound for weight management, is a dual GLP-1/GIP receptor agonist
However, the FDA will consider a compounded drug product to be essentially a copy of commercially available drug products if the compound contains the same active pharmaceutical ingredients as two or more commercially available drugs in the same, similar, or easily substitutable strength, and if the commercially available drugs can be used by the same route of administration as the prescribed compound
weight lifting) or tissue damage and is responsible for muscle hypertrophy
In both trails, sample size, discontinuation rate, mean diabetes duration, and percentage of patients with established ASCVD were comparable
It's a catastrophic failure at the molecular level